Evidence map›Paper›PMID 26380735›Full record

ArticleJournal of thoracic disease2015

Clarithromycin might attenuate the airway inflammation of smoke-exposed asthmatic mice via affecting HDAC2.

Min Hao, Jiangtao Lin, Jun Shu, Xiaoyan Zhang, Qiongzhen Luo, Lin Pan, Jing Guo

Open access · greenAbstract read
In one paragraph

Article in Journal of thoracic disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Novel approaches to the management of noneosinophilic asthma.Therapeutic advances in respiratory disease · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Min Hao1 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 2 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 3 Clinical Research Institute of China-Japan Friendship Hospital, Beijing 100029, China ; 4 Department of Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China ; 5 Graduate School Peking Union Medical College &Chinese Academy of Medical Science, Beijng 100029, China.
Jiangtao Lin1 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 2 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 3 Clinical Research Institute of China-Japan Friendship Hospital, Beijing 100029, China ; 4 Department of Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China ; 5 Graduate School Peking Union Medical College &Chinese Academy of Medical Science, Beijng 100029, China.
Jun Shu1 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 2 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 3 Clinical Research Institute of China-Japan Friendship Hospital, Beijing 100029, China ; 4 Department of Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China ; 5 Graduate School Peking Union Medical College &Chinese Academy of Medical Science, Beijng 100029, China.
Xiaoyan Zhang1 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 2 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 3 Clinical Research Institute of China-Japan Friendship Hospital, Beijing 100029, China ; 4 Department of Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China ; 5 Graduate School Peking Union Medical College &Chinese Academy of Medical Science, Beijng 100029, China.
Qiongzhen Luo1 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 2 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 3 Clinical Research Institute of China-Japan Friendship Hospital, Beijing 100029, China ; 4 Department of Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China ; 5 Graduate School Peking Union Medical College &Chinese Academy of Medical Science, Beijng 100029, China.
Lin Pan1 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 2 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 3 Clinical Research Institute of China-Japan Friendship Hospital, Beijing 100029, China ; 4 Department of Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China ; 5 Graduate School Peking Union Medical College &Chinese Academy of Medical Science, Beijng 100029, China.
Jing Guo1 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 2 Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China ; 3 Clinical Research Institute of China-Japan Friendship Hospital, Beijing 100029, China ; 4 Department of Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029, China ; 5 Graduate School Peking Union Medical College &Chinese Academy of Medical Science, Beijng 100029, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSmoke has been proved to be one of the most dangerous ingredients leading to the unsatisfying treatment response of asthmatics to inhaled corticosteroids (ICS) therapy. Macrolides, a class of antibiotics, possess the traits of immunomodulation and anti-inflammation besides antimicrobial activity. Given that studies on the efficacy of macrolides on the refractory asthma patient have diverting conclusions, this article was carried on to investigate the effects of macrolide on the airway inflammation of smoke-exposed asthmatic mice.

methodsBALB/c mice were chosen to be the subjects of this study. They were raised to establish asthma model (OVA group); and one asthma group were exposed to the smoke (SEA group), one asthma group were treat with clarithromycin (CAM group) after smoke exposure. Control group mice were used as parallel comparison. Total inspiratory resistance (RL), expiratory resistance of the lung (Re) and lung compliance (Cdyn) were the main index to evaluate airway hyperresponsiveness (AHR). The histopathological change was studied to assess lung tissue inflammation. Cell counts in bronchoalveolar lavage fluid (BALF) were also tested to represent airway inflammation. IL-4 and CXCL1 in BALF and serum were also used to evaluate the airway inflammation. Histone deacelytase2 (HDAC2) activity of lung tissues was measure by assay kit. HDAC2 expression in the lung tissue had been detected by western blot.

resultsRe, RL and Cdyn were monitored to represent airway responsiveness. All of the three indicators in SEA group were significantly different from control group, while clarithromycin improved airway responsiveness and the three indicator were statistically significant (P<0.01). Histopathology observation had showed massive infiltration of inflammatory cells in both OVA group and SEA group, while inflammation infiltration attenuated in CAM group. Total cell counts in SEA group was much higher than that in CAM group (P=0.019), so were neutrophils (P=0.022) and eosinophils (P=0.042); while macrophages in SEA group decreased when compared to CAM group (P=0.026), IL-4 and CXCL1 level in CAM group were significantly decreased in comparison to those in SEA group (P=0.031, P=0.017). HDAC2 activity in SEA group decreased significantly when compared to control group (P=0.010); while HDAC2 activity in CAM group was improved and significantly better than that in SEA group (P=0.038). The expression of HADC2 in CAM group improved significantly when compared to that in SEA group (P=0.022).

conclusionsClarithromycin could improve AHR and attenuate airway inflammation in smoke exposed asthmatic mice which may involve HDAC2. Macrolides might have the potential to serve as the adjunctive treatment to some refractory asthmatics who are smokers or passive smokers.

Indexed as

Asthmahistone deacelytase2 (HDAC2)inflammationsmoke

Identifiers

PMID26380735
PMCPMC4522485
OpenAlexW1923853085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.